Celgene Corp. , the biopharmaceutical company that agreed last week to be acquired by Bristol-Myers Squibb Co. in a mega-deal valued at $74 billion, provided 2019 profit and sales outlooks that were above expectations. The company said it expects adjusted earnings per share, which excludes non-recurring items, of $10.60 to $10.80, above the the FactSet consensus of $10.31. Revenue is expected to be $17.0 billion to $17.2 billion, Celgene said, while the FactSet consensus is for $16.95 billion. The company expects 2019 sales of its blockbuster drug Revlimid to rise 11% to about $10.8 billion, compared with the FactSet consensus of $10.85 billion. “Multiple clinical and regulatory milestones are expected in 2019 to advance our late-stage portfolio and accelerate our early-stage pipeline,” Chief Executive Mark Alles said. The stock slipped 0.5% in premarket trade, while Bristol-Myers shares edged up 0.2%. Despite a 21% surge last Thursday after the Bristol-Myers deal was announced, Celgene shares have still lost 19.1% over the past 12 months through Friday, while the Dow Jones Industrial Average has lost 7.4%.